



Maguire, M. G., Shaffrer, J., Ying, G., Chakravarthy, U., Berg, K., Bragadottir, R., deculier, E., Huot, L., Kodjikian, L., Martin , D. F., Reeves, B., Rogers, C., Schauwvileghe, A.-S. M. E., & Schlingemann, R. (2017). Serious Adverse Events with Bevacizumab or Ranibizumab for Age-Related Macular Degeneration: Meta-analysis of Individual Patient Data. *Ophthalmology Retina*, 1(5), 357-381. <https://doi.org/10.1016/j.oret.2016.12.015>

Peer reviewed version

License (if available):
CC BY-NC-ND

Link to published version (if available):
[10.1016/j.oret.2016.12.015](https://doi.org/10.1016/j.oret.2016.12.015)

[Link to publication record on the Bristol Research Portal](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at <http://www.sciencedirect.com/science/article/pii/S2468653016301671>. Please refer to any applicable terms of use of the publisher.

University of Bristol – Bristol Research Portal

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/brp-terms/>

Serious Adverse Events with Bevacizumab or Ranibizumab for Age-related Macular Degeneration: Meta-analysis of Individual Patient Data

The Bevacizumab-Ranibizumab International Trials Group ‡

Writing Committee:

Maureen G. Maguire, PhD	Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
James Shaffer, MS	Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Gui-shuang Ying, PhD	Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Usha Chakravarthy, PhD, FRCS	Institute of Clinical Science, The Queen's University of Belfast, Belfast, Ireland
Karina Berg, MD	Department of Ophthalmology, Oslo University Hospital, Oslo, Norway
Ragnheiður Bragadóttir MD, PhD	Department of Ophthalmology, Oslo University Hospital, Oslo, Norway
Evelyne Decullier, PhD	Hospices Civils de Lyon, Département Recherche Clinique et Innovation, Lyon, France; Université de Lyon, Lyon France
Laure Huot, PharmD, PhD	Hospices Civils de Lyon, Département Recherche Clinique et Innovation, Lyon, France; Université de Lyon, Lyon France
Laurent Kodjikian, MD, PhD	Hospices Civils de Lyon, Croix-Rousse University Hospital, Department of Ophthalmology; Université de Lyon, Lyon, France
Daniel F. Martin, MD	Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio United States
Barnaby C. Reeves, DPhil	Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK
Chris A. Rogers, PhD	Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK
Ann-Sofie M.E. Schauwvlieghe, MD	Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Reinier O. Schlingemann, MD	Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

‡ The members of the Bevacizumab-Ranibizumab International Trials Group are listed in the Appendix (available at <http://www.aaojournal.org>).

This article contains additional online-only material. The following should appear online-only: Appendix and Figures 2 to 5.

Corresponding Author:

Maureen G. Maguire, PhD 215 615 1501 (V) 215 615 1520 (Fax)

maguirem@mail.med.upenn.edu

Department of Ophthalmology

3535 Market Street, Suite 700, Philadelphia PA 19104

Part of this material was presented at the ARVO 2016 Annual Meeting.

Dr. Chakravarthy reports grants and lecture fees from Bayer, grants from Roche, and grants and payment for Advisory Board participation from Novartis. Dr. Kodjikian reports grants from Bayer and Novartis and personal fees from Allergan, Alcon, Bayer, Novartis and Zeiss. Dr. Maguire reports personal fees from Genentech/Roche, Dr. Rogers reports grants from UK National Institute for Health Research. Dr. Schlingemann reports personal fees from Bayer and Novartis. Dr. Ying reports personal fees from Chengdu Kanghong Biotech co., Ltd. Drs. Maguire, Martin, Ying and Mr. Shaffer reports grants from the National Eye Institute.

Running head: Meta-analysis of safety of bevacizumab and ranibizumab

Reprints requests to: Maureen Maguire, PhD, CATT Coordinating Center, University of Pennsylvania, 3535 Market Street, Suite 700, Philadelphia, PA 19104-3309

Supported by cooperative agreements U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828, and R21 EY023689 from the National Eye Institute, National Institutes of Health, Department of Health and Human Services.

Registration numbers: ClinicalTrials.gov: NCT00593450, NCT00710229, NCT01127360, NCT01170767; ISRCTN number: ISRCTN92166560; Netherlands National Trial Register number: NTR1704 .

ABSTRACT

Topic: A comparison between ranibizumab and bevacizumab of the incidence of systemic serious adverse events (SAEs) among patients with neovascular age-related macular degeneration (nAMD) who participated in a large-scale randomized trial. Use of individual patient data, rather than aggregate data, allowed adjustment for strong predictors of SAEs.

Clinical relevance: Relative safety of ranibizumab and bevacizumab is important in choosing an anti-VEGF drug for the hundreds of thousands of patients with nAMD treated each year worldwide.

Methods: Results of a Cochrane aggregate meta-analysis of the relative efficacy and safety of bevacizumab and ranibizumab that used searches of bibliographic databases and clinical trial registries as of March 14, 2014 and hand searching were reviewed to identify 6 large-scale, multicenter clinical trials. Individual patient data on SAEs, assigned drug and dosing regimen, and baseline prognostic factors were requested from the leaders of the 6 trials. A two-stage approach was used to estimate relative risks and 95% confidence intervals (CIs) from Cox proportional hazards models adjusting for baseline prognostic factors. The primary outcome measure was development of ≥ 1 SAE; secondary outcome measures were death, arteriothrombotic events, events associated with systemic anti-VEGF therapy, and events not associated with systemic anti-VEGF therapy.

Results: Individual patient data were received from 5 trials to provide information on 3052 patients. There were no large imbalances between drug groups on baseline factors. The adjusted relative risk (95% CI) for bevacizumab relative to ranibizumab was 1.06 [(0.84, 1.35); $p=0.61$] for ≥ 1 SAEs. For secondary outcomes, adjusted relative risks were 0.99 [(0.69, 1.43); $p=0.97$] for death, 0.89 [(0.62, 1.28); $p=0.53$] for arteriothrombotic events, 1.10 [(0.81, 1.50); $p=0.54$] for events related to anti-VEGF treatment, and 1.11 [(0.87, 1.40); $p=0.40$] for events not related to anti-VEGF treatment.

Conclusion: Our findings support the absence of large differences in risk of systemic serious adverse events between these two anti-VEGF drugs; i.e., relative risks of ≥ 1.5 are unlikely. Because additional head-to-head trials are unlikely, any further investigation of differential risk between anti-VEGF agents will only be achieved through post-marketing surveillance or through the interrogation of healthcare databases.

The management and prognosis of patients with neovascular age-related macular degeneration (AMD) changed dramatically in 2005 with the release of results from Phase III clinical trials of intravitreally administered ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA), an inhibitor of all active forms of vascular endothelial growth factor (VEGF).^{1,2} On average, eyes treated with ranibizumab gained visual acuity while untreated eyes or eyes treated with photodynamic laser therapy lost substantial visual acuity. While waiting for approval from regulatory agencies in the United States and Europe, ophthalmologists began using intravitreal bevacizumab off label to treat neovascular AMD because it was structurally similar to ranibizumab (Avastin; Genentech, Inc., South San Francisco, CA), available for use because it had been approved for treatment of cancer, and was inexpensive. Short-term outcomes related to vision and retinal morphology after treatment with bevacizumab appeared similar to those of ranibizumab, leading to rapid adoption of bevacizumab as first-line therapy. The fact that after ranibizumab was approved by the Food and Drug Administration, ranibizumab was sold for approximately \$2000 per dose in the United States compared to \$50 for bevacizumab, amplified the need for comparison of longer term efficacy and safety between the two drugs.³

Planning for large-scale, multicenter clinical trials of the two drugs was initiated in 6 different countries. These multicenter clinical trials were: the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) in the United States, the Alternative Treatments to Inhibit VEGF in Age-related Choroidal Neovascularization (IVAN) in the United Kingdom, the Groupe d'Etude Français Avastin versus Lucentis dans la DMLA néovasculaire (GEFAL) in France, the Multicenter Anti-VEGF Trial in Austria (MANTA), Lucentis Compared to Avastin Study (LUCAS) in Norway, and Bevacizumab and Ranibizumab in Age-related Macular Degeneration (BRAMD) in the Netherlands.⁴⁻¹² In 2011, CATT was the first of the trials to provide 1-year results.⁴ The mean change in visual acuity under treatment with bevacizumab was non-inferior to the mean change in visual acuity under treatment with ranibizumab. The results on efficacy from the other multicenter clinical trials have been consistent with no

134 difference or only a small difference in change in visual acuity between drugs after the initiation
135 of treatment; a recent meta-analysis yielded a mean difference (95% confidence interval [CI]) of
136 -0.5 letters (-1.6 to +0.6), with a negative difference indicating less improvement in eyes treated
137 with bevacizumab.¹³

138 However, the results from one of the clinical trials raised concerns on the safety of
139 bevacizumab relative to ranibizumab. In CATT, the proportion of patients with 1 or more
140 systemic serious adverse events (SAEs) at 1 year was higher with bevacizumab than
141 ranibizumab (24.1% vs. 19.0%; adjusted relative risk, 1.29; 95% CI [1.01, 1.66]) and the
142 elevated risk persisted at 2 years (39.9% vs. 31.7%; adjusted relative risk, 1.30; 95% CI [1.07,
143 1.57]; P=0.009).^{4,5} Rates of death and arteriothrombotic events were similar for the two drugs.
144 As the results from other clinical trials became available, several groups of investigators
145 performed meta-analyses of overall SAEs and specific adverse events based on the aggregate
146 data.¹³⁻¹⁹ The most comprehensive analysis of SAEs was a Cochrane review led by Moja
147 consisting of 3665 patients with 3356 from the 6 multicenter clinical trials noted above and 309
148 patients from 3 smaller-scale studies.¹⁵ The combined risk ratio for 1 or more systemic adverse
149 events was 1.08, 95% CI (0.90, 1.31). Similar to the researchers conducting previous meta-
150 analyses, Moja et al concluded that there was no strong evidence of a difference in risk but that
151 the data available was not sufficient to rule out clinically important differential risks, particularly
152 for specific adverse events.

153 The purpose of the present investigation was to use individual patient data, rather than
154 aggregate data, from the large-scale multicenter clinical trials evaluating bevacizumab and
155 ranibizumab for treatment of neovascular age-related macular degeneration to estimate the
156 relative risk of serious systemic adverse events and selected specific SAEs adjusted for
157 prognostic baseline variables. Although randomization is expected to provide treatment groups
158 that are balanced on predisposing conditions, small imbalances on strong prognostic factors
159 such as age, smoking, hypertension, and use of anti-coagulant medications can artificially

inflate or deflate the difference in risk between the two drugs. Accounting for covariates also may increase the precision of the estimates of the relative risk.

METHODS

Clinical Trials Included

Investigators for a recent Cochrane aggregate meta-analysis of the relative efficacy and safety of intravitreal bevacizumab and ranibizumab searched electronic bibliographic databases and clinical trial registries as of March 14, 2014 and used hand searching to identify 5249 records that might address the topic.¹³ Nine trials were identified by the Cochrane investigators. We targeted for this review the six multicenter, randomized clinical trials that compared bevacizumab to ranibizumab, reported counts for patients with 1 or more SAEs, had at least 1 patient reported to have an SAE, and had results published or presented at a national meeting by December 2015. Eligibility criteria for all the trials specified enrollment of eyes with active neovascularization.

Specification of Outcomes and Effect Measures

The primary outcome for the review was the percentage of patients experiencing 1 or more SAEs as defined by the Food and Drug Administration of the United States and the European Medicines Agency.^{20,21} This definition includes all deaths, life-threatening events, hospitalizations, events resulting in persistent or significant disability, important medical events, and congenital anomalies. Secondary outcomes were the specific SAEs of death, arteriothrombotic events as defined by the Antiplatelet Trialists' Collaboration (APTC), events previously associated with systemic anti-VEGF treatment (arteriothrombotic events [including but not limited to myocardial, cerebellar, and cerebral ischemia and infarction, coronary artery occlusion, transient ischemic attack, cerebrovascular accidents, and embolism], systemic hemorrhage [including duodenal, gastric, gastrointestinal, rectal, respiratory tract, urogenital, cerebral, intracranial hemorrhage and hematoma], cardiac failure [including congestive heart failure], venous thrombotic events [including pulmonary embolism, deep vein thrombosis, and

thrombosis], hypertension [including hypertensive heart disease and accelerated hypertension], vascular death), and events not previously associated with systemic anti-VEGF treatment.²²⁻²⁴ Because of an imbalance reported from CATT, gastrointestinal hemorrhages were also summarized. The difference in risk was summarized by the relative risk (hazard ratio) and the associated 95% confidence interval.

Data Collection and Statistical Analysis

The Coordinating Center for CATT managed the data and performed the statistical analyses for the review. The lead author or primary contact person as listed in a registry of clinical trials was invited to provide individual patient data. Data were to be provided in two electronic data files containing only de-identified data. The first file contained age at enrollment, gender, drug (bevacizumab or ranibizumab), dosing regimen (pro re nata, monthly, or treat-and-extend), study eye (right or left), smoking status at baseline (current, past, or never), diabetes at baseline (yes or no), use of medications for hypertension at baseline (yes or no), treatment of the fellow eye with anti-VEGF drugs during the study period (drug and duration of use), use of aspirin at baseline (yes or no), use of an anti-coagulant at baseline (yes or no), and number of days between enrollment and the last date of data collection for SAEs. The individual patient characteristics at baseline were chosen because they are known to be strong prognostic factors for one or more of the outcomes of interest. The second file contained one record for each SAE and included the number of days between study enrollment and the SAE, the Medical Dictionary for Regulatory Activities (MedDRA) code number, and MedDRA preferred term for the SAE. The period of observation was 2 years after study entry for CATT and IVAN and 1 year for the other 4 studies.

A two-stage approach was used for each meta-analysis.^{25,26} In the first stage, a Cox proportional hazards model of the outcome of interest was used for each individual clinical trial to provide a relative risk adjusted for baseline prognostic factors and to provide the associated 95% confidence interval for the risk of using bevacizumab compared to using ranibizumab.

Only the first observation of the outcome of interest was included in the analysis. The Cox models included dosing regimen (for CATT and IVAN only because these trials include both monthly and as-needed regimens), age, gender, smoking status, diabetes status, use of medications for or a diagnosis of hypertension, use of aspirin, and use of anti-coagulants when data for these variables were available. For the second stage, OpenMeta[Analyst] statistical software for meta-analyses was used to produce a weighted average of the trial specific relative risk from the first stage (http://www.cebm.brown.edu/open_meta/ accessed 10/20/2015). Random effects models using maximum likelihood estimation were chosen to reflect both the within-study variability (95% CIs estimated in stage 1) and the between-study variability (the difference between the point estimates from stage 1 and the pooled estimate).²⁷ Heterogeneity among trial results was evaluated with the I^2 statistic. For purposes of comparison, an unadjusted meta-analysis was performed with OpenMeta[Analyst] using aggregate data as for stage 2 of the adjusted meta-analysis. Individual patient data were not provided from MANTA.⁹ As a secondary analysis, the unadjusted risk estimates for 1 or more SAEs and for death from based on the publication of 1-year MANTA results were used for the second stage of the adjusted meta-analysis. Because the conversion from the published data to the other outcomes of interest could not be made without more details on type of the SAEs, no secondary analyses were performed for the other outcomes of interest.

The data files from the 5 clinical trial groups providing individual patient data were checked for completeness of the data requested and for consistency with published aggregate results. Data files for CATT, IVAN, GEFAL, and LUCAS, matched the published aggregate findings for the safety analysis with respect to number of patients and number of patients with 1 or more systemic SAE in each treatment group. Serious ocular adverse events were not counted as systemic adverse events for this analysis.¹¹ There was 1 less patient assigned to bevacizumab in the data files from BRAMD than reported in published results.¹² Nine patients in LUCAS, who had no serious adverse events, were excluded from the efficacy analysis in LUCAS because of

238 serious non-compliance with the treatment protocol and were excluded from the adjusted
239 analysis in this report. When data on use of medications for hypertension were not available,
240 data on a diagnosis of hypertension were used instead.

241

RESULTS

The baseline data available from each clinical trial are summarized in Table 1. Among the five clinical trials providing individual patient data, age, gender, diabetes status, and hypertension status (as defined in the parent trial) were available in all trials. There were only small imbalances between the bevacizumab and ranibizumab groups on the baseline characteristics.

There were 403 (26.6%) patients among 1513 treated with bevacizumab and 366 (23.8%) among 1539 treated with ranibizumab who had 1 or more systemic SAE. The numbers of patients in each treatment group in each study are provided in Table 2. Adjusted meta-analysis results are shown in Figure 1 and compared to the unadjusted results in Table 3. The pooled adjusted relative risk for bevacizumab compared to ranibizumab was 1.06, 95% CI (0.84, 1.35). The adjusted relative risk differs little from the unadjusted relative risk of 1.08. When the aggregate data from MANTA was included in the adjusted analysis, the relative risk was 1.09, 95% CI (0.89, 1.35). The adjusted relative risk for death was 0.99, 95% CI (0.69, 1.43) (Figure 2 available at <http://www.aaojournal.org>). When the aggregate data from MANTA was included in the adjusted analysis, the relative risk was 1.01, 95% CI (0.71, 1.45). Estimated risk for APTC arteriothrombotic events was lower for bevacizumab (0.89) but with the 95% confidence interval spanning (0.62, 1.28) (Figure 3 available at <http://www.aaojournal.org>). The adjusted relative risks for systemic SAEs related to anti-VEGF treatment and those not related to anti-VEGF treatment were nearly identical (1.10 and 1.11, respectively) (Figures 4, 5 available at <http://www.aaojournal.org>). There were too few gastrointestinal hemorrhages reported (1 for ranibizumab in GEFAL, 1 for ranibizumab in LUCAS) to add any meaningful information to the imbalance reported in CATT (7 for bevacizumab, 2 for ranibizumab).

The percentage of the variability in relative risks due to heterogeneity across studies, rather than to sampling error, is given by the I^2 statistic in each of the Figures. Heterogeneity was moderate for the proportion of patients with 1 or more systemic SAE (50%) and systemic SAEs

not related to systemic anti-VEGF treatments (59%), substantially less (30%) for arteriothrombotic events, and 0% for death and events related to systemic anti-VEGF treatment.

DISCUSSION

The individual patient data meta-analyses yielded no significant differences in risk of systemic SAEs between bevacizumab and ranibizumab. Thus, while the point estimate for relative risk indicated an approximate 10% increase with bevacizumab relative to ranibizumab for most categories of SAE, a similar 10% decrease for arteriothrombotic events was found. However, the confidence intervals for the relative risks spanned values, both for increased risk and decreased risk with bevacizumab, that would be clinically important for events such as death, cerebro- and cardio-vascular events, and cancer. The adjusted analyses produced results indicating less risk with bevacizumab than in the unadjusted analyses; however, the reduction was minor.

Now that 10 years have passed since the introduction of bevacizumab and ranibizumab for treatment of neovascular age-related macular degeneration, new head-to-head trials are no longer likely to be performed. Although the recent Cochrane meta-analyses of systemic SAEs and the unadjusted meta-analysis based on aggregated data reported here did not include the same set of trials, they yielded similar relative risks of approximately 1.1 for 1 or more SAEs through 1 or 2 years. A trial in India of 120 patients with no adverse events reported,²⁸ a trial in the United States of 28 patients with 2 deaths reported in 20 patients treated with bevacizumab (1 meckel cell carcinoma and 1 cause unknown),²⁹ and a trial in Germany registered on ClinicalTrials.gov but without presentation at a national meeting or in a peer-reviewed journal were included in the meta-analysis by Moja but not the current one.³⁰ Moja noted that, in a personal communication, the German researchers reported SAEs in 21% (22/107) of patients treated with bevacizumab and in 11% (6/54) of patients treated with ranibizumab.¹⁵ Because

small imbalances on strong risk factors such as age, smoking history, hypertension, diabetes, and aspirin and anti-coagulant use can result in biased estimates of difference in risk, this review was initiated to find out whether such imbalances might have influenced the result of meta-analyses that used aggregate data from the clinical trials.

There are some weaknesses in this meta-analysis. First, all the trials were of modest size (<1200 patients each). Second, although there was a common definition of an SAE across trials, the methods of ascertaining the occurrence of an SAE may have varied among trials. Third, the dosing intervals varied across the trials. Comparisons between the drugs were made within each dosing regimen, but the monthly, as needed, and treat and extend approaches were used among the trials. Fourth, individual patient data could not be obtained for one of the clinical trials and only a secondary analysis using aggregate data from that trial could be performed. Fifth, there was moderate heterogeneity across the 5 trials in the proportion of patients with 1 or more systemic SAE and systemic SAEs not related to systemic anti-VEGF treatments, due mainly to results from LUCAS. We attribute this to random variation because eligibility, dose, and visual acuity results in LUCAS were similar to those in the other trials and the ascertainment of SAEs was made by staff masked to study drug. In addition to the strength of the study of being able to account for possible imbalances in prognostic factors through use of patient-level data, the present study employed survival analysis methods that incorporate not only the occurrence of an SAE but also the time since initiation of treatment, thus providing a more precise assessment of differential risk than simply comparing the cumulative numbers at either 1 or 2 years of follow-up.

The meta-analyses on individual patient data in this review, as well as previous meta-analyses on aggregate data, support the conclusion that large differences between bevacizumab and ranibizumab in risk of systemic serious adverse events; i.e., relative risks of ≥ 1.5 , are unlikely. Although the estimated relative risks indicate an approximate 10% increase

318 for most types of SAEs and a 10% decrease in arteriothrombotic events for bevacizumab, these
319 point estimates have confidence intervals that include up to a 50% increase or decrease in risk.
320 In the absence of additional large-scale clinical trials, further investigation of the differential risk
321 of these anti-VEGF agents can be carried out only through epidemiologic surveillance using
322 administrative or healthcare databases.

REFERENCES

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med* 2006;355:1419-31.
2. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *N Engl J Med* 2006;355:1432-44.
3. Martin DF, Maguire MG, Fine SL. Identifying and eliminating the roadblocks to comparative-effectiveness research. *N Engl J Med* 2010;363:105-7.
4. The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. *N Engl J Med* 2011;364:1897-1908. Epub 2011 Apr 28.
5. The CATT Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2-year results. *Ophthalmology* 2012;119:1388–98.
6. The IVAN Study Investigators. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration. One-year findings from the IVAN randomized trial. *Ophthalmology* 2012;119:1399–1411.
7. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. *Lancet* 2013;382:1258-67.
8. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL Noninferiority Randomized Trial. *Ophthalmology* 2013;120:2300–9.
9. Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. *Br J Ophthalmol* 2013;97:266–71.

10. Berg K, Pederson TR, Sandvik L, Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. *Ophthalmology* 2015;122:146-52.
11. Avery RL. Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (*Ophthalmology* 2015;122:146-52). *Ophthalmology* 2016;123:e14-6.
12. Schauwvlieghe AM, Dijkman G, Hooymans JM, et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. The BRAMD study. *PLoS One*.;11(5):e0153052, 2016.
13. Solomon SD, Lindsley KB, Krzystolik MG, et al. Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration: Findings from a Cochrane Systematic Review. *Ophthalmology* 2016;123:70-77.
14. Schmucker C; Ehlken C; Agostini HT; et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. *PLoS ONE*; 7(8):e42701, 2012.
15. Moja L, Lucenteforte E, Kwag K, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration: *Cochrane Database Syst Rev*. 2014 Sep 15;9:CD011230.
16. Wang W, Zhang X. Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis. *PLoS ONE*. 9(10):e109744, 2014.
17. Kodjikian L , Decullier E , Souied EH , et al. Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials. *Graefes Archive for Clinical & Experimental Ophthalmology* 2014; 252:1529-37.

18. Thulliez M; Angoulvant D; Le Lez ML; et al. Cardiovascular events and bleeding risk associated with intravitreal antivasular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. *JAMA Ophthalmology* 2014; 132:1317-26.
19. Chen G; Li W; Tzekov R; et al. Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. *Retina* 2015;35:187-93.
20. U.S. Food and Drug Administration. What is a Serious Adverse Event? Available at <http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm>. Accessed May 17, 2016.
21. Guideline on good pharmacovigilance practices (GVP). Annex I – Definitions. 12 December 2012 EMA/876333/2011 Rev. 1
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129131.pdf. Accessed May 17, 2016.
22. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ* 1994; 308:81-106. [Erratum, *BMJ* 1994;308:1540.]
23. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. *Nat Rev Clin Oncol* 2009;6:465–77.
24. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. *JAMA* 2008;300:2277–85.
25. Turner RM, Omar RZ, Yang M, et al. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. *Stat Med* 2000;19:3417-32.
26. Simmonds MC, Higgins JPT, Stewart LA, et al. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. *Clinical Trials* 2005; 2:209–217.

27. Higgins JPT, Green S, eds. Cochrane Handbook of Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at www.cochrane-handbook.org. Accessed December 21, 2015.
28. Biswas P, Sengupta S, Choudhary R, Home S, et al. Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. *Indian J. Ophthalmol* 2011;59:191–6.
29. Subramanian ML, Abedi G, Ness S, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. *Eye* 2010;24:1708–15.
30. NCT00559715. Prevention of vision loss in patients with age-related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting. Available at clinicaltrials.gov/show/NCT00559715. Accessed July 11, 2016.

410

FIGURE LEGEND

411

412 Figure 1. Forest Plot for the Adjusted Relative Risk for 1 or More Systemic Serious
413 Adverse Events for Bevacizumab Compared to Ranibizumab.

Studies	Estimate (95% C.I.)
CATT	1.278 (1.055, 1.548)
IVAN	1.043 (0.764, 1.424)
GEFAL	1.154 (0.671, 1.985)
LUCAS	0.569 (0.354, 0.915)
BRAMD	1.337 (0.785, 2.277)
Overall ($I^2=49.63\%$, $P=0.036$)	1.064 (0.841, 1.346)




Figure 2. (Supplementary) Forest Plot for the Adjusted Relative Risk for Death for Bevacizumab Compared to Ranibizumab




Figure 3. (Supplementary) Forest Plot for the Adjusted Relative Risk for Antiplatelet Trialists' Collaboration (APTC) Arteriothrombotic Event as for Bevacizumab Compared to Ranibizumab




Figure 4. (Supplementary) Forest Plot for the Adjusted Relative Risk for Events Related to Anti-VEGF

Treatment for Bevacizumab Compared to Ranibizumab




Figure 5. (Supplementary) Forest Plot for the Adjusted Relative Risk for Events Not Related to Anti-VEGF Treatment for Bevacizumab Compared to Ranibizumab




Table 1. Distribution of Baseline Characteristics Available from Each Clinical Trial by Drug

Characteristic	Clinical Trial					Overall
	CATT	IVAN	GEFAL	LUCAS	BRAMD	
Drug, N						
Bevacizumab	586	296	246	220	165	1513
Ranibizumab	599	314	239	221	166	1539
Age (yrs), mean						
Bevacizumab	79.7	77.7	79.5	78.6	77.1	78.8
Ranibizumab	78.8	77.8	79.0	78.0	77.0	78.3
Female (%)						
Bevacizumab	62.1	61.2	62.2	70.6	55.2	62.4
Ranibizumab	61.4	58.9	70.3	64.2	55.4	62.0
Current or past smoker (%)						
Bevacizumab	57.7	62.5	NA	55.5	54.6	58.0
Ranibizumab	56.8	63.7	NA	52.0	51.8	57.0
Diabetic (%)						
Bevacizumab	18.3	9.1	11.8	7.0	10.9	13.0
Ranibizumab	16.7	11.8	10.9	6.4	12.7	12.9
Hypertension (%)						
Bevacizumab	70.3	61.2	61.8	57.9	57.0	63.9
Ranibizumab	68.6	59.9	53.1	53.2	66.9	62.0
Aspirin (%)						
Bevacizumab	50.9	31.4	NA	29.0	NA	41.3
Ranibizumab	45.9	27.1	NA	30.3	NA	37.7
Anticoagulant (%)						
Bevacizumab	16.6	4.4	NA	7.7	NA	11.5
Ranibizumab	17.7	6.1	NA	9.1	NA	12.8

NA = Not available.

Table 2. Systemic Serious Event and its Type from Each Clinical Trial by Drug

Characteristic	CATT	IVAN	GEFAL	LUCAS	BRAMD	Total
N						
Bevacizumab	586	296	246	220	165	1513
Ranibizumab	599	314	239	221	166	1539
≥1 SAE: n (%)						
	234	80	30	29	30	403
Bevacizumab	(39.9%)	(27.0%)	(12.2%)	(13.2%)	(18.2%)	(26.6%)
	190	81	24	45	26	366
Ranibizumab	(31.7%)	(25.8%)	(10.0%)	(20.4%)	(15.7%)	(23.8%)
Death: n (%)						
	36	15	2	4	1	58
Bevacizumab	(6.1%)	(5.1%)	(0.8%)	(1.8%)	(0.6%)	(3.8%)
	32	15	3	7	1	58
Ranibizumab	(5.3%)	(4.8%)	(1.3%)	(3.2%)	(0.6%)	(3.8%)
APTC: n (%)						
	29	20	2	3	4	58
Bevacizumab	(4.9%)	(6.8%)	(0.8%)	(1.4%)	(2.4%)	(3.8%)
	28	25	1	9	2	65
Ranibizumab	(4.7%)	(8.0%)	(0.4%)	(4.1%)	(0.9%)	(4.2%)
VEGF-related: n (%)						
	62	14	4	6	3	89
Bevacizumab	(10.6%)	(4.7%)	(1.6%)	(2.7%)	(1.8%)	(5.9%)
	45	19	4	8	3	79
Ranibizumab	(7.5%)	(6.1%)	(1.7%)	(3.6%)	(1.8%)	(5.1%)
Not VEGF-related: n (%)						
	202	73	27	25	29	356
Bevacizumab	(34.4%)	(24.7%)	(11.0%)	(11.4%)	(17.6%)	(23.5%)
	170	70	20	40	23	323
Ranibizumab	(28.4%)	(22.2%)	(8.4%)	(18.1%)	(13.9%)	(21.0%)

NA is not available.

APTC = Antiplatelet Trialists' Collaboration arteriothrombotic events

VEGF is vascular endothelial growth factor

Table 3. Summary of Estimated Relative Risks of Systemic Serious Adverse Events after Treatment with Bevacizumab Compared to Ranibizumab

Systemic Serious Event Type	Bevacizumab (N=1513) With Event n (%)	Ranibizumab (N=1539) With Event n. (%)	Relative Risk (95% CI)		P-value Adjusted Model
			Unadjusted	Adjusted	
≥1 event	403 (26.6%)	366 (23.8%)	1.08 (0.90,1.30)	1.06 (0.84,1.35)	0.61
Death	58 (3.8%)	58 (3.8%)	1.03 (0.72,1.48)	0.99 (0.69,1.43)	0.97
APTC	58 (3.8%)	65 (4.2%)	0.93 (0.66,1.32)	0.89 (0.62,1.28)	0.53
VEGF-related	89 (5.9%)	79 (5.1%)	1.16 (0.86,1.56)	1.10 (0.81,1.50)	0.54
Not VEGF-related	356 (23.5%)	323 (21.0%)	1.14 (1.00,1.30)	1.11 (0.87,1.40)	0.40

APTC is Antiplatelet Trialists' Collaboration arteriothrombotic events

VEGF is vascular endothelial growth factor

Precis

A meta-analysis on individual patient data supports the conclusion that large differences between bevacizumab and ranibizumab in risk of systemic serious adverse events; i.e., relative risks of ≥ 1.5 , are unlikely.

Credit Roster for the Bevacizumab-Ranibizumab International Trials Group

Credit Roster for the BRAMD

Clinical Centers (Ordered by Number of Patients enrolled)

Certified Roles at Clinical Centres: Clinic Coordinator (CC), Data Entry Staff (DE), Participating Ophthalmologist (O), Ophthalmic Photographer (OP); Optical Coherent Tomography Technician (OCT), Principal Investigator (PI), Refractionist (R), Visual Acuity Examiner (VA)

AMC: Reinier O. Schlingemann (PI), Frank D. Verbraak (O), Marie van Schooneveld (O), Monique Wezel (CC), Henk Stam (VA/R), Christa Jansen-Kok (VA/R/OCT/DE), Ans Althoff (VA/R/OCT) Douwe Bakker (CC/VA/R/OCT/DE), Anette van der Zee (DE)

Erasmus MC: Johannes R. Vingerling (PI), Naus- Postema (O), De Roo Hertoge (O), C. Klaver (O), E. Kilic (O), Yvonne Noordzij (CC/DE/VA/R/OCT), Jeanette Noordzij (CC/DE/VA/R/OCT), Anjo Vermij (VA/R), Ada Hooghart (VA/R)

LUMC: Greetje Dijkman (PI), Ingrid Boesten (CC/DE/VA/R), C. Kiewiet de Jonge (VA/R), M. Kromhart-de Haas (VA/R), Cora Mollinger (VA/R), J.W. Zwaan (VA/R), Lou Brink (VA/R), Anneke Boolman (VA/R)

UMCG: Johanna Hooymans (PI), Nicole Kamminga (O), Angela Huiskamp (O), Postma (O) Marijke Meinen (CC/DE/R/VA), L. Uwantegé (VA/R), H.R. Luurtsema (VA/R), J.F. Eisses (VA/R/OCT), Westra (OP), Ronardel de Lavalette (O), Van De Pol (O), J van Nieuwpoort, j, Tiggelman, T Ezenga, Brouwen, F. Schuit, Ufkes, H. Egberts, G de Fretes

UMCN: Carel B. Hoyng (PI), Agnes de Vries (CC), Elke Huntink (CC), Asha Kalisingh (CC), Liesbeth Hoeks (VA/R), Hans Hermans (VA/R), Angeline Rottelveel (VA/R/OCT), J. Weeda (VA/R/OP/OCT), Chantal Van Ast (OCT)

OMC Haarlem: Remko van Hierdam (VA/R), Annemieke Coops (VA/R), R.W. Hierden (OCT), Kees Corstanje (VA/R), Madelon Jansen (VA/R/OCT), Nikki van denBerg (VA/R/OCT)

Zonnestraal Hilversum: Bianca Ban Leeuwen (VA/R/DE), Gerrie Dantuma (VA/R/OCT), Serge Koning (VA/R/OCT), Maurice van Baekel (OCT/VA/R), Mike Selders (VA/R/OCT), Martine Zandee (VA/R/OCT), Maaïke Goudriaan (VA/R/OCT), Annemarieke Langen (VA/R/OCT), Robert W.H van de Mortel (VA/R/OCT)

Resource Centers

Chairman's Office and Coordinating Center(Academic Medical Center, Amsterdam, the Netherlands): R.O. Schlingemann, MD PhD(Chair/PI); F.D Verbraak, MD (Vice-Chair; Academic Medical Center, Amsterdam, the Netherlands) M.G.W Dijkgraaf (methodologist), R. De Haan (methodologist), A.H. Zwinderman, SCP (Biostatistician); A.M.E. Schauwvlieghe, MD (Medical

Monitor); Selma Mehmedovic (Protocol Monitor); Jaqueline Van Daele (CRA), Irmgard Corten (Systems Analyst); Eric Veenstra (Financial Administrator); Yolanda Strubel (Database developer)

OCT Reading Center: F.D. Verbraak, MD PhD(PI), A.M.E. Schauwvlieghe, MD (reader), Douwe Bakker (reader)

Fundus Photograph Reading Center (Reading Centre, Moorfields Eye Hospital): Peto T, MD PhD(PI); Peter Blows (reader)

Data and Safety Monitoring Committee: Ringens PJ, MD, PhD (chair); R. Geskus (Biostatistician), MD; R. Van Leeuwen, MD PhD

Credit Roster for Comparison of AMD Treatments Trials (CATT)

Clinical Centers (Ordered by Number of Patients Enrolled)

Certified Roles at Clinical Centers: Clinic Coordinator (CC), Data Entry Staff (DE), Participating Ophthalmologist (O), Ophthalmic Photographer (OP); Optical Coherent Tomography Technician (OCT), Principal Investigator (PI), Refractionist (R), Visual Acuity Examiner (VA)

Vitreoretinal Surgery, PA (Edina, MN): David F. Williams, MD (PI); Sara Beardsley, COA (VA/R); Steven Bennett, MD (O); Herbert Cantrill, MD (O); Carmen Chan-Tram, COA (VA/R); Holly Cheshier, CRA, COT, OCTC (OP); Kathryn Damato, COT (VA); John Davies, MD (O); Sundeep Dev, MD (O); Julianne Enloe, CCRP, COA (CC); Gennaro Follano (OP/OCT); Peggy Gilbert, COA (VA/R); Jill Johnson, MD (O); Tori Jones, COA (OCT); Lisa Mayleben, COMT (CC/VA/R/OCT); Robert Mittra, MD (O); Martha Moos, COMT, OSA (VA/R); Ryan Neist, COMT (VA/R); Neal Oestreich, COT (CC); Polly Quiram, MD (O); Robert Ramsay, MD (O); Edwin Ryan, MD (O); Stephanie Schindeldecker, OA (VA/R); John Snater, COA (VA); Trenise Steele, COA (VA); Dwight Selders, COA (VA/R); Jessica Tonsfeldt, AO (OP/OCT); Shelly Valardi, COT (VA/R).

Texas Retina Associates (Dallas, TX): Gary Edd Fish, MD (PI); Hank A. Aguado, CRA (OP/OCT); Sally Arceneaux (CC/VA/R); Jean Arnwine (CC); Kim Bell, COA (VA/R); Tina Bell (CC/OCT); Bob Boleman (OP); Patricia Bradley, COT (CC); David Callanan, MD (O); Lori Coors, MD (O); Jodi Creighton, COA (VA/R); Timothy Crew, COA (OCT); Kimberly Cummings (OP/OCT); Christopher Dock (OCT); Karen Duignan, COT (VA/R); Dwain Fuller, MD (O); Keith Gray (OP/OCT); Betsy Hendrix, COT, ROUB (OCT); Nicholas Hesse (OCT); Diana Jaramillo, COA (OCT); Bradley Jost, MD (O); Sandy Lash (VA/R); Laura Lonsdale, CCRP (DE); Michael Mackens (OP/OCT); Karin Mutz, COA (CC); Michael Potts (VA/R); Brenda Sanchez (VA/R); William Snyder, MD (O); Wayne Solley, MD (O); Carrie Tarter (VA/R); Robert Wang, MD (O); Patrick Williams, MD (O).

Southeastern Retina Associates (Knoxville, TN): Stephen L. Perkins, MD (PI); Nicholas Anderson, MD (O); Ann Arnold, COT (VA/R); Paul Blais (OP/OCT); Joseph Googe, MD (O); Tina T. Higdon, (CC); Cecile Hunt (VA/R); Mary Johnson, COA (VA/R); James Miller, MD (O); Misty Moore (VA/R); Charity K. Morris, RN (CC); Christopher Morris (OP/OCT); Sarah Oelrich, COT (OP/OCT); Kristina Oliver, COA (VA/R); Vicky Seitz, COT (VA/R); Jerry Whetstone (OP/OCT).

Retina Vitreous Consultants (Pittsburgh, PA): Bernard H. Doft (PI); Jay Bedel, RN, (CC); Robert Bergren, MD (O); Ann Borthwick (VA/R); Paul Conrad, MD, PHD (O); Amanda Fec (OCT); Christina

Fulwylie (VA/R); Willia Ingram (DE); Shawnique Latham (VA/R); Gina Lester (VA/R); Judy Liu, MD (O); Louis Lobes, MD (O); Nicole M. Lucko, (CC); Holly Mechling (CC); Lori Merlotti, MS, CCRC (CC); Keith McBroom (OCT); Karl Olsen, MD (O); Danielle Puskas, COA (VA/R); Pamela Rath, MD (O); Maria Schmucker (CC); Lynn Schueckler (OCT); Christina Schultz (CC/VA/R); Heather Shultz (OP/OCT); David Steinberg, CRA (OP/OCT); Avni Vyas, MD (O); Kim Whale (VA/R); Kimberly Yeckel, COA, COT (VA/R).

Ingalls Memorial Hospital/Illinois Retina Associates (Harvey, IL): David H. Orth, MD (PI); Linda S. Arredondo, RN (CC/VA); Susan Brown (VA/R); Barbara J. Ciscato (CC/VA); Joseph M. Civantos, MD (O); Celeste Figliulo (VA/R); Sohail Hasan, MD (O); Belinda Kosinski, COA (VA/R); Dan Muir (OP/OCT); Kiersten Nelson (OP/OCT); Kirk Packo, MD (O); John S. Pollack, MD (O); Kourous Rezaei, MD (O); Gina Shelton (VA); Shannya Townsend-Patrick (OP/OCT); Marian Walsh, CRA (OP/OCT).

West Coast Retina Medical Group, Inc. (San Francisco, CA): H. Richard McDonald, MD (PI); Nina Ansari (VA/R/OCT); Amanda Bye, (OP/OCT); Arthur D. Fu, MD (O); Sean Grout (OP/OCT); Chad Indermill (OCT); Robert N. Johnson, MD (O); J. Michael Jumper, MD (O); Silvia Linares (VA/R); Brandon J. Lujan, MD (O); Ames Munden (OP/OCT); Meredith Persons (CC); Rosa Rodriguez (CC); Jennifer M. Rose (CC); Brandi Teske, COA (VA/R); Yesmin Urias (OCT); Stephen Young (OP/OCT).

Retina Northwest, P.C. (Portland, OR): Richard F. Dreyer, MD (PI); Howard Daniel (OP/OCT); Michele Connaughton, CRA (OP/OCT); Irvin Handelman, MD (O); Stephen Hobbs (VA/R/OCT); Christine Hoerner (OP/OCT); Dawn Hudson (VA/R/OCT); Marcia Kopfer, COT (CC/VA/R/OCT); Michael Lee, MD (O); Craig Lemley, MD (O); Joe Logan, COA (OP/OCT); Colin Ma, MD (O); Christophe Mallet (VA/R); Amanda Milliron (VA/R); Mark Peters, MD (O); Harry Wohlsein, COA (OP).

Retinal Consultants Medical Group, Inc. (Sacramento, CA): Joel A. Pearlman, MD, PHD (PI); Margo Andrews (OP/OCT); Melissa Bartlett (OCT); Nanette Carlson (CC/OCT); Emily Cox (VA/R); Robert Equi, MD (O); Marta Gonzalez (VA/R/OCT); Sophia Griffin (OP/OCT); Fran Hogue (VA/R); Lance Kennedy (OP/OCT); Lana Kryuchkov (OCT); Carmen Lopez (VA/R); Danny Lopez (OP/OCT); Bertha Luevano (VA/R); Erin McKenna, (CC); Arun Patel, MD (O); Brian Reed, MD (O); Nyla Secor (CC/OCT); Iris R. Sison (CC); Tony Tsai, MD (O); Nina Varghis, (CC); Brooke Waller (OCT); Robert Wendel, MD (O); Reina Yebra (OCT).

Retina Vitreous Center, PA (New Brunswick, NJ): Daniel B. Roth, MD (PI); Jane Deinzer, RN (CC/VA/R); Howard Fine, MD MHSC (O); Flory Green (VA/R); Stuart Green, MD (O); Bruce Keyser, MD (O); Steven Leff, MD (O); Amy Leviton (VA/R); Amy Martir (OCT); Kristin Mosenthine (VA/R/OCT); Starr Muscle, RN (CC); Linda Okoren (VA/R); Sandy Parker (VA/R); Jonathan Prenner, MD (O); Nancy Price (CC); Deana Rogers (OP/OCT); Linda Rosas (OP/OCT); Alex Schlosser (OP/OCT); Loretta Studenko (DE); Thea Tantom (CC); Harold Wheatley, MD (O).

Vision Research Foundation/Associated Retinal Consultants, P.C. (Royal Oak, MI): Michael T. Trese, MD (PI); Thomas Aaberg, MD (O); Tina Bell (VA/R/OP/OCT); Denis Bezaire, CRA (OP/OCT); Craig Bridges, CRA (OP/OCT); Doug Bryant, CRA (OP/OCT); Antonio Capone, MD (O); Michelle Coleman, RN (CC); Christina Consolo, CRA, COT (OP/OCT); Cindy Cook, RN (CC); Candice DuLong (VA/R); Bruce Garretson, MD (O); Tracy Grooten (VA/R); Julie Hammersley, RN (CC); Tarek Hassan, MD (O); Heather Jessick (OP/OCT); Nanette Jones (VA/R/OP/OCT); Crystal Kinsman (VA/R); Jennifer Krumlauf (VA/R); Sandy Lewis, COT (VA/R/OP/OCT); Heather Locke (VA/R); Alan Margherio, MD (O); Debra Markus, COT (CC/VA/R/OP/OCT); Tanya Marsh, COA (OP/OCT); Serena Neal (CC); Amy Noffke, MD (O); Kean Oh, MD (O); Clarence Pence (OP/OCT); Lisa Preston (VA/R); Paul Raphaelian, MD (O); Virginia R. Regan, RN, CCRP (VA/R); Peter Roberts (OP/OCT); Alan Ruby, MD (O); Ramin Sarrafizadeh, MD, PHD (O); Marissa Scherf (OP/OCT); Sarita Scott (VA/R); Scott Sneed, MD (O);

Lisa Staples (CC); Brad Terry (VA/R/OP/OCT); Matthew T. Trese (OCT); Joan Videtich, RN (VA/R); George Williams, MD (O); Mary Zajechowski, COT, CCRC (CC/VA/R).

The Retina Institute (St. Louis, MO): Daniel P. Joseph, MD (PI); Kevin Blinder, MD (O); Lynda Boyd, COT (VA/R); Sarah Buckley (OP/OCT); Meaghan Crow (VA/R); Amanda Dinatale, (OCT); Nicholas Engelbrecht, MD (O); Bridget Forke (OP/OCT); Dana Gabel (OP/OCT); Gilbert Grand, MD (O); Jennifer Grillion-Cerone (VA/R); Nancy Holekamp, MD (O); Charlotte Kelly, COA (VA/R); Ginny Nobel, COT (CC); Kelly Pepple (VA/R); Matt Raeber, (OP/OCT); P. Kumar Rao, MD (O); Tammy Ressel, COT (VA/R); Steven Schremp (OCT); Merrilee Sgorlon (VA/R); Shantia Shears, MA (CC); Matthew Thomas, MD (O); Cathy Timma (VA/R); Annette Vaughn, (OP/OCT); Carolyn Walters, COT (CC/VA/R); Rhonda Weeks, CRC (CC/VA/R); Jarrod Wehmeier (OP/OCT); Tim Wright (OCT).

The Retina Group of Washington (Chevy Chase, MD): Daniel M. Berinstein, MD (PI); Aida Ayyad (VA/R); Mohammed K. Barazi, MD (O); Erica Bickhart (CC/VA/R); Tracey Brady (OCT); Lisa Byank, MA (CC); Alysia Cronise, COA (VA/R); Vanessa Denny (VA/R); Courtney Dunn (VA/R); Michael Flory (OP/OCT); Robert Frantz (OP/OCT); Richard A. Garfinkel, MD (O); William Gilbert, MD (O); Michael M. Lai, MD, PHD (O); Alexander Melamud, MD (O); Janine Newgen (VA/R); Shamekia Newton (CC); Debbie Oliver (CC); Michael Osman, MD (O); Reginald Sanders, MD (O); Manfred von Fricken, MD (O).

Retinal Consultants of Arizona (Phoenix, AZ): Pravin Dugel, MD (PI); Sandra Arenas (CC); Gabe Balea (OCT); Dayna Bartoli (OP/OCT); John Bucci (OP/OCT); Jennifer A. Cornelius (CC); Scheleen Dickens, (CC); Don Doherty (OP/OCT); Heather Dunlap, COA (VA/R); David Goldenberg, MD (O); Karim Jamal, MD (O); Norma Jimenez (OP/OCT); Nicole Kavanagh (VA/R); Derek Kunitomo, MD (O); John Martin (OP/OCT); Jessica Miner, RN (VA/R); Sarah Mobley, CCRC (CC/VA/R); Donald Park, MD (O); Edward Quinlan, MD (O); Jack Sipperley, MD (O); Carol Slagle (R); Danielle Smith (OP/OCT); Miguelina Yafchak (OCT); Rohana Yager, COA (OP/OCT).

Casey Eye Institute (Portland, OR): Christina J. Flaxel, MD (PI); Steven Bailey, MD (O); Peter Francis, MD, PHD (O); Chris Howell, (OCT); Thomas Hwang, MD (O); Shirley Ira, COT (VA/R); Michael Klein, MD (O); Andreas Lauer, MD (O); Teresa Liesegang, COT (CC/VA/R); Ann Lundquist, (CC/VA/R); Sarah Nolte (DE); Susan K. Nolte (VA/R); Scott Pickell (OP/OCT); Susan Pope, COT (VA/R); Joseph Rossi (OP/OCT); Mitchell Schain (VA/R); Peter Steinkamp, MS (OP/OCT); Maureen D. Toomey (CC/VA/R); Debora Vahrenwald, COT (VA/R); Kelly West (OP/OCT).

Emory Eye Center (Atlanta, GA): Baker Hubbard, MD (PI); Stacey Andelman, MMSC, COMT (CC/VA/R); Chris Bergstrom, MD (O); Judy Brower, COMT (CC/VA/R); Blaine Cribbs, MD (O); Linda Curtis (VA/R); Jannah Dobbs (OP/OCT); Lindreth DuBois, MED, MMSC, CO, COMT (CC/VA/R); Jessica Gaultney (OCT); Deborah Gibbs, COMT, CCRC (VA/R); Debora Jordan, CRA (OP/OCT); Donna Leef, MMSC, COMT (VA/R); Daniel F. Martin, MD (O); Robert Myles, CRA (OP); Timothy Olsen, MD (O); Bryan Schwent, MD (O); Sunil Srivastava, MD (O); Rhonda Waldron, MMSC, COMT, CRA, RDMS (OCT).

Charlotte Eye, Ear, Nose & Throat Associates/Southeast Clinical Research (Charlotte, NC): Andrew N. Antoszyk, MD (PI); Uma Balasubramaniam, COA (OCT); Danielle Brooks, CCRP (VA/R); Justin Brown, MD (O); David Browning, MD, PHD (O); Loraine Clark, COA (OP/OCT); Sarah Ennis, CCRC (VA/R); Susannah Held (OCT); Jennifer V. Helms, CCRC, (CC); Jenna Herby, CCRC (CC); Angie Karow, CCRP (VA/R); Pearl Leotaud, CRA (OP/OCT); Caterina Massimino (OCT); Donna McClain, COA (OP/OCT); Michael McOwen, CRA (OP/OCT); Jennifer Mindel, CRA, COA (OP/OCT); Candace Pereira, CRC (CC); Rachel Pierce, COA (VA/R); Michele Powers (OP/OCT); Angela Price, MPH, CCRC (CC); Jason Rohrer (CC); Jason Sanders, MD (O).

California Retina Consultants (Santa Barbara, CA): Robert L. Avery, MD (PI); Kelly Avery (VA/R); Jessica Basefsky (CC/OCT); Liz Beckner (OP); Alessandro Castellarin, MD (O); Stephen Couvillion, MD (O); Jack Giust (CC/OCT); Matthew Giust (OP); Maan Nasir, MD (O); Dante Pieramici, MD (O); Melvin Rabena (VA/R); Sarah Risard (VA/R/OCT/DE); Robert See, MD (O); Jerry Smith (VA/R); Lisha Wan (VA/R).

Mayo Clinic (Rochester, MN): Sophie J. Bakri, MD (PI); Nakhleh Abu-Yaghi, MD (O); Andrew Barkmeier, MD (O); Karin Berg, COA (VA/R); Jean Burrington, COA (VA/R); Albert Edwards, MD (O); Shannon Goddard, COA (OP/OCT); Shannon Howard (VA/R); Raymond Iezzi, MD (O); Denise Lewison, COA (OP/OCT); Thomas Link, CRA (OP/OCT); Colin A. McCannel, MD (O); Joan Overend (VA/R); John Pach, MD (O); Margaret Ruszczyk, CCRP (CC); Ryan Shultz, MD (O); Cindy Stephan, COT (VA/R); Diane Vogen (CC).

Dean A. McGee Eye Institute (Oklahoma City, OK): Reagan H. Bradford Jr, MD (PI); Vanessa Bergman, COA, CCRC (CC); Russ Burris (OP/OCT); Amanda Butt, CRA (OP/OCT); Beth Daniels, COA (CC); Connie Dwiggin, CCRC (CC); Stephen Fransen, MD (O); Tiffany Guerrero (CC/DE); Darin Haivala, MD (O); Amy Harris (CC); Sonny Icks (CC/DE); Ronald Kingsley, MD (O); Lena Redden (VA/R); Rob Richmond (OP/OCT); Brittany Ross (VA/R); Kammerin White, CCRC (VA/R); Misty Youngberg, COA, CCRC (VA/R).

Ophthalmic Consultants of Boston (Boston, MA): Trexler M. Topping, MD (PI); Steve Bennett (OCT); Sandy Chong (VA/R); Mary Ciotti, COA (CC); Tina Cleary, MD (O); Emily Corey (VA/R); Dennis Donovan (OP/OCT); Albert Frederick, MD (O); Lesley Freese (CC/VA/R); Margaret Graham (OP/OCT); Natalya Gud, COA (VA/R); Taneika Howard (VA/R); Mike Jones (OP/OCT); Michael Morley, MD (O); Katie Moses (VA/R); Jen Stone (VA/R); Robin Ty, COA (VA/R); Torsten Wiegand, PHD, MD (O); Lindsey Williams (CC); Beth Winder (CC).

Tennessee Retina, P.C. (Nashville, TN): Carl C. Awh, MD (PI); Michelle Amonette (OCT); Everton Arrindell, MD (O); Dena Beck (OCT); Brandon Busbee, MD (O); Amy Dilback (OP/OCT); Sara Downs (VA/R); Allison Guidry, COA (VA/R); Gary Gutow, MD (O); Jackey Hardin (VA/R); Sarah Hines, COA (CC); Emily Hutchins (VA/R); Kim LaCivita, MA (OP/OCT); Ashley Lester (OP/OCT); Larry Malott (OP/OCT); MaryAnn McCain, RN, CNOR (CC); Jayme Miracle (VA/R); Kenneth Moffat, MD (O); Lacy Palazzotta (VA/R); Kelly Robinson, COA (VA/R); Peter Sonkin, MD (O); Alecia Travis (OP/OCT); Roy Trent Wallace, MD (O); Kelly J. Winters, COA (CC); Julia Wray (OP/OCT).

Retina Associates Southwest, P.C. (Tucson, AZ): April E. Harris, MD (PI); Mari Bunnell (OCT); Katrina Crooks (VA/R); Rebecca Fitzgerald, CCRC (CC/OCT); Cameron Javid, MD (O); Corin Kew (VA/R); Erica Kill, VAE (VA/R); Patricia Kline (VA/R); Janet Kreienkamp (VA/R); Maricruz Martinez (CC/OCT); Roy Ann Moore, OMA (CC/OCT); Egbert Saavedra, MD (O); LuAnne Taylor, CSC (CC/OCT); Mark Walsh, MD (O); Larry Wilson (OP).

Midwest Eye Institute (Indianapolis, IN): Thomas A. Ciulla, MD (PI); Ellen Coyle, COMT (VA/R); Tonya Harrington, COA (VA/R); Charlotte Harris, COA (VA/OCT); Cindi Hood (OCT); Ingrid Kerr, COA (VA/R); Raj Maturi, MD (O); Dawn Moore (OCT); Stephanie Morrow, COA (OP); Jennifer Savage, COA (VA); Bethany Sink, COA (CC/VA/R); Tom Steele, CRA (OP); Neelam Thukral, CCRC (CC/OCT); Janet Wilburn, COA (CC).

National Ophthalmic Research Institute (Fort Myers, FL): Joseph P. Walker, MD (PI); Jennifer Banks (VA/R); Debbie Ciampaglia (OP/OCT); Danielle Dyshanowitz (VA/R); Jennifer Frederick, CRC (CC); A. Tom Ghuman, MD (O); Richard Grodin, MD (O); Cheryl Kiesel, CCRC (CC); Eileen Knips,

RN, CCRC, CRA (OP/OCT); Jonathan McCue (VA/R); Maria Ortiz (VA/R); Crystal Peters, CCRC (CC); Paul Raskauskas, MD (O); Etienne Schoeman (OP/OCT); Ashish Sharma, MD (O); Glenn Wing, MD (O), Rebecca Youngblood (CC).

University of Wisconsin Madison (Madison, WI): Suresh R. Chandra, MD (PI); Michael Altaweel, MD (O); Barbara Blodi, MD (O); Kathryn Burke, BA (VA/R); Kristine A. Dietzman, (CC); Justin Gottlieb, MD (O); Gene Knutson (OP/OCT); Denise Krolnik (OP/OCT); T. Michael Nork, MD (O); Shelly Olson (VA/R); John Peterson, CRA (OP/OCT); Sandra Reed (OP/OCT); Barbara Soderling (VA/R); Guy Somers (VA/R); Thomas Stevens, MD (O); Angela Wealti, (CC).

Duke University Eye Center (Durham, NC): Srilaxmi Bearely, MD (PI); Brenda Branchaud (VA/R); Joyce W. Bryant, COT, CPT (CC/VA/R); Sara Crowell (CC/VA); Sharon Fekrat, MD (O); Merritt Gammage (OP/OCT); Cheala Harrison, COA (VA/R); Sarah Jones (VA); Noreen McClain, COT, CPT, CCRC (VA/R); Brooks McCuen, MD (O); Prithvi Mruthyunjaya, MD (O); Jeanne Queen, CPT (OP/OCT); Neeru Sarin, MBBS (VA/R); Cindy Skalak, RN, COT (VA/R); Marriner Skelly, CRA (OP/OCT); Ivan Suner, MD (O); Ronnie Tomany (OP/OCT); Lauren Welch (OP/OCT).

University of California-Davis Medical Center (Sacramento, CA): Susanna S. Park, MD, PHD (PI); Allison Cassidy (VA/R); Karishma Chandra (OP/OCT); Idalew Good (VA/R); Katrina Imson (CC); Sashi Kaur (OP/OCT); Helen Metzler, COA, CCRP (CC/VA/R); Lawrence Morse, MD, PHD (O); Ellen Redenbo, ROUB (OP/OCT); Marisa Salvador (VA/R); David Telander, MD (O); Mark Thomas, CRA (OCT); Cindy Wallace, COA (CC).

University of Louisville School of Medicine, KY (Louisville, KY): Charles C. Barr, MD (PI); Amanda Battcher (VA/R); Michelle Bottorff, COA (CC/OCT); Mary Chasteen (VA/R); Kelly Clark (VA/R); Diane Denning, COT (OCT); Debra Schoen (OP); Amy Schultz (OP); Evie Tempel, CRA, COA (OP); Lisa Wheeler, COT (VA/R); Greg K. Whittington, MPS, PSY (CC).

Retina Associates of Kentucky (Lexington, KY): Thomas W. Stone, MD (PI); Todd Blevins (OP/OCT); Michelle Buck, COT, (VA/R/OCT); Lynn Cruz, COT (CC); Wanda Heath (VA/R); Diana Holcomb (VA/R); Rick Isernhagen, MD (O); Terri Kidd, COA (OCT); John Kitchens, MD (O); Cathy Sears, CST, COA (VA/R); Ed Slade, CRA, COA (OP/OCT); Jeanne Van Arsdall, COA (VA/R); Brenda VanHoose, COA (VA/R); Jenny Wolfe, RN (CC); William Wood, MD (O).

Colorado Retina Associates (Denver, CO): John Zilis, MD (PI); Carol Crooks, COA (VA/R); Larry Disney (VA/R); Mimi Liu, MD (O); Stephen Petty, MD (O); Sandra Sall, ROUB, COA (CC/VA/R/OP/OCT).

University of Iowa Hospitals & Clinics (Iowa City, IA): James C. Folk, MD (PI); Tracy Aly, CRA (OP/OCT); Abby Brotherton (VA); Douglas Critser, CRA (OP/OCT); Connie J. Hinz, COT, CCRC (CC/VA/R); Stefani Karakas, CRA (OP/OCT); Valerie Kirschner (VA); Cheyanne Lester (VA/R); Cindy Montague, CRA (OP/OCT); Stephen Russell, MD (O); Heather Stockman (VA/R); Barbara Taylor, CCRC (VA/R); Randy Verdick, FOPS (OP/OCT), Jean Walshire (CC).

Retina Specialists (Towson, MD): John T. Thompson, MD (PI) ; Barbara Connell (VA/R); Maryanth Constantine (CC); John L. Davis Jr (VA/R); Gwen Holsapple (VA/R); Lisa Hunter (OP/OCT); C. Nicki Lenane (CC/VA/R/OP/OCT); Robin Mitchell (CC); Leslie Russel, CRA (OP/OCT); Raymond Sjaarda, MD (O).

Retina Consultants of Houston (Houston, TX): David M. Brown, MD (PI); Matthew Benz, MD (O); Llewellyn Burns (OCT); JoLene G. Carranza, COA, CCRC (CC); Richard Fish, MD (O); Debra Goates

(VA/R); Shayla Hay (VA/R); Theresa Jeffers, COT (VA/R); Eric Kegley, CRA, COA (OP/OCT); Dallas Kubecka (VA/R); Stacy McGilvra (VA/R); Beau Richter (OCT); Veronica Sneed, COA (VA/R); Cary Stoeber (OCT); Isabell Tellez (VA/R); Tien Wong, MD (O).

Massachusetts Eye and Ear Infirmary/Harvard Vanguard Medical Associates (Boston, MA):

Ivana Kim, MD (PI); Christopher Andreoli, MD (O); Leslie Barresi, CRA, COA, OCT-C (VA/OP/OCT); Sarah Brett (OP); Charlene Callahan (OP); Karen Capaccioli (OCT); William Carli, COA (VA/R/OCT); Matthew Coppola, COA (VA); Nicholas Emmanuel (CC); Claudia Evans, OD (VA/R); Anna Fagan, COA (VA/R); Marcia Grillo (OCT); John Head, CRA, OCT-C (OP/OCT); Troy Kieser, COA, OCT-C (CC/VA/R); Elaine Lee, COA (VA); Ursula Lord, OD (VA/R); Edward Miretsky (CC); Kate Palitsch (OP/OCT); Todd Petrin, RN (OCT); Liz Reader (CC); Svetlana Reznichenko, COA (VA); Mary Robertson, COA (VA); Justin Smith, OD (VA/R); Demetrios Vavvas, MD, PHD (O).

Palmetto Retina Center (West Columbia, SC): John Wells, MD (PI); Cassie Cahill (VA/R); W. Lloyd Clark, MD (O); Kayla Henry (VA/R); David Johnson, MD (O); Peggy Miller (CC/VA/R); LaDetrick Oliver, COT (OP/OCT); Robbin Spivey (OP/OCT); Tiffany Swinford (VA/R); Mallie Taylor (CC).

Retina and Vitreous of Texas (Houston, TX): Michael Lambert, MD (PI); Kris Chase (OP/OCT); Debbie Fredrickson, COA (VA/R); Joseph Khawly, MD, FACS (O); Valerie Lazarte (VA/R); Donald Lowd (OP/OCT); Pam Miller (CC); Arthur Willis, MD (O).

Long Island Vitreoretinal Consultants (Great Neck, NY): Philip J. Ferrone, MD (PI); Miguel Almonte (OCT); Rachel Arnott, (CC); Ingrid Aviles (VA/R/OCT); Sheri Carbon (VA/R); Michael Chitjian (OP/OCT); Kristen D'Amore (CC); Christin Elliott (VA/R); David Fastenberg, MD (O); Barry Golub, MD (O); Kenneth Graham, MD (O); AnnMarie Lavana (CC); Laura Murphy (VA/R); Amanda Palomo (VA/R); Christina Puglisi (VA/R); David Rhee, MD (O); Juan Romero, MD (O); Brett Rosenblatt, MD (O); Glenda Salcedo (OP/OCT); Marianne Schlameuss, RN (CC); Eric Shakin, MD (O); Vasanti Sookhai (VA/R).

Wills Eye Institute/ Mid Atlantic Retina (Philadelphia, PA): Richard Kaiser, MD (PI); Elizabeth Affel, MS, OCT-C (OCT); Gary Brown, MD (O); Christina Centinaro (CC); Deborah Fine, COA (OCT); Mitchell Fineman, MD (O); Michele Formoso (CC); Sunir Garg, MD (O); Lisa Grande (VA/R); Carolyn Herbert (VA/R); Allen Ho, MD (O); Jason Hsu, MD (O); Maryann Jay (OCT); Lisa Lavetsky (OCT); Elaine Liebenbaum (OP); Joseph Maguire, MD (O); Julia Monsonago (OP/OCT); Lucia O'Connor (OCT); Lisa Pierce (CC); Carl Regillo, MD (O); Maria Rosario (DE); Marc Spirn, MD (O); James Vander, MD (O); Jennifer Walsh (VA/R).

Ohio State University Eye Physicians & Surgeons-Retina Division (Dublin, OH): Frederick H. Davidorf, MD (PI); Amanda Barnett (OP/OCT); Susie Chang, MD (O); John Christoforidis, MD (O); Joy Elliott (CC); Heather Justice (VA/R); Alan Letson, MD (O); Kathrynne McKinney, COMT (CC); Jeri Perry, COT (VA/R); Jill A. Salerno, COA (CC); Scott Savage (OP); Stephen Shelley (OCT).

Retina Associates of Cleveland (Beachwood, OH): Lawrence J. Singerman, MD (PI); Joseph Coney, MD (O); John DuBois (OP/OCT); Kimberly DuBois, LPN, CCRP, COA (VA/R); Gregg Greanoff, CRA (OP/OCT); Dianne Himmelman, RN, CCRP (CC); Mary Ilc, COT (VA/R); Elizabeth Mcnamara (VA/R/OP); Michael Novak, MD (O); Scott Pendergast, MD (O); Susan Rath, PA-C (CC); Sheila Smith-Brewer, CRA (OP/OCT); Vivian Tanner, COT, CCRP (VA/R); Diane E. Weiss, RN, (CC); Hernando Zegarra, MD (O).

Retina Group of Florida (Fort Lauderdale, FL): Lawrence Halperin, MD (PI); Patricia Aramayo (OCT); Mandeep Dhalla, MD (O); Brian Fernandez, MD (OP/OCT); Cindy Fernandez, MD (CC); Jaclyn

Lopez (CC); Monica Lopez (OCT); Jamie Mariano, COA (VA/R); Kellie Murphy, COA (OCT); Clifford Sherley, COA (VA/R); Rita Veksler, COA (OP/OCT).

Retina-Vitreous Associates Medical Group (Beverly Hills, CA): Firas Rahhal, MD (PI); Razmig Babikian (DE); David Boyer, MD (O); Sepideh Hami (DE); Jeff Kessinger (OP/OCT); Janet Kurokouchi (CC); Saba Mukarram (VA/R); Sarah Pachman (VA/R); Eric Protacio (OCT); Julio Sierra (VA/R); Homayoun Tabandeh, MD, MS, FRCP (O); Adam Zamboni (VA/R).

Elman Retina Group, P.A. (Baltimore, MD): Michael Elman, MD (PI); Jennifer Belz (CC); Tammy Butcher (CC); Theresa Cain (OP/OCT); Teresa Coffey, COA (VA/R); Dena Firestone (VA/R); Nancy Gore (VA/R); Pamela Singletary (VA/R); Peter Sotirakos (OP/OCT); JoAnn Starr (CC).

University of North Carolina at Chapel Hill (Chapel Hill, NC): Travis A. Meredith, MD (PI); Cassandra J. Barnhart, MPH (CC/VA/R); Debra Cantrell, COA (VA/R/OP/OCT); RonaLyn Esquejo-Leon (OP/OCT); Odette Houghton, MD (O); Harpreet Kaur (VA/R); Fatoumatta NDure, COA (CC).

Ophthalmologists Enrolling Patients but No Longer Affiliated with a CATT Center: Ronald Glatzer, MD (O); Leonard Joffe, MD (O); Reid Schindler, MD (O).

Resource Centers

Chairman's Office (Cleveland Clinic, Cleveland, OH): Daniel F. Martin, MD (Chair); Stuart L. Fine, MD (Vice-Chair; University of Colorado, Denver, CO); Marilyn Katz (Executive Assistant).

Coordinating Center (University of Pennsylvania, Philadelphia, PA): Maureen G. Maguire, PhD (PI); Mary Brightwell-Arnold, SCP (Systems Analyst); Ruchira Glaser, MD (Medical Monitor); Judith Hall (Protocol Monitor); Sandra Harkins (Staff Assistant); Jiayan Huang, MS (Biostatistician); Alexander Khvatov, MS (Systems Analyst); Kathy McWilliams, CCRP (Protocol Monitor); Susan K. Nolte (Protocol Monitor); Ellen Peskin, MA, CCRP (Project Director); Maxwell Pistilli, MS, MEd (Biostatistician); Susan Ryan (Financial Administrator); Allison Schnader (Administrative Coordinator); Gui-Shuang Ying, PhD (Senior Biostatistician).

OCT Reading Center (Duke University, Durham, NC): Glenn Jaffe, MD (PI); Jennifer Afrani-Sakyl (CATT PowerPoint Presentations); Brannon Balsley (OCT Technician Certifications); Linda S. Bennett (Project Manager); Adam Brooks (Reader/SD-Reader); Adrienne Brower-Lingsch (Reader); Lori Bruce (Data Verification); Russell Burns (Senior Technical Analyst/Senior Reader/SD Reader/OCT Technician Certifications); Dee Busian (Reader); John Choong (Reader); Lindsey Cloaninger (Reader Reliability Studies/ Document Creation/CATT PPT Files); Francis Char DeCroos (Research Associate); Emily DuBois (Data Entry); Mays El-Dairi (Reader/SD-Reader); Sarah Gach (Reader); Katelyn Hall (Project Manager/Reader Reliability Studies/ Data Verification/Document Creation); Terry Hawks (Reader); ChengChenh Huang (Reader); Cindy Heydary (Senior Reader/Quality Assurance Coordinator/SD Reader/Data Verification); Alexander Ho (Reader, Transcription); Shashi Kini (Data Entry/Transcription); Michelle McCall (Data Verification); Daaimah Muhammad (Reader Feedback); Jayne Nicholson (Data Verification); Jeanne Queen (Reader/SD-Reader); Pamela Rieves (Transcription); Kelly Shields (Senior Reader); Cindy Skalak (Reader); Adam Specker (Reader); Sandra Stinnett (Biostatistician); Sujatha Subramaniam (Reader); Patrick Tenbrink (Reader); Cynthia Toth, MD (Director of Grading); Aaron Towe (Reader); Kimberly Welch (Data Verification); Natasha Williams (Data Verification); Katrina Winter (Senior Reader); Ellen Young (Senior Project Manager).

Fundus Photograph Reading Center (University of Pennsylvania, Philadelphia, PA): Juan E. Grunwald, MD (PI); Judith Alexander (Director); Ebenezer Daniel, MBBS, MS, MPH, PhD (Director); Elisabeth Flannagan (Administrative Coordinator); E. Revell Martin (Reader); Candace Parker (Reader); Krista Sepielli (Reader); Tom Shannon (Systems Analyst); Claressa Whearry (Data Coordinator).

National Eye Institute, National Institutes of Health: Maryann Redford, DDS, MPH (Program Officer).

Committees

Executive Committee: Daniel F. Martin, MD (chair); Robert L. Avery, MD; Sophie J. Bakri, MD; Ebenezer Daniel, MBBS, MS, MPH; Stuart L. Fine, MD; Juan E. Grunwald, MD; Glenn Jaffe, MD; Marcia R. Kopfer, BS, COT; Maureen G. Maguire, PhD; Travis A. Meredith, MD; Ellen Peskin, MA, CCRP; Maryann Redford, DDS, MPH; David F. Williams, MD.

Operations Committee: Daniel F. Martin, MD (chair); Linda S. Bennett; Ebenezer Daniel, MBBS, MS, MPH; Frederick L. Ferris III, MD; Stuart L. Fine, MD; Juan E. Grunwald, MD; Glenn Jaffe, MD; Maureen G. Maguire, PhD; Ellen Peskin, MA, CCRP; Maryann Redford, DDS, MPH; Cynthia Toth, MD.

Clinic Monitoring Committee: Ellen Peskin, MA, CCRP (chair); Mary Brightwell-Arnold, SCP; Joan DuPont; Maureen G. Maguire, PhD; Kathy McWilliams, CCRP; Susan K. Nolte.

Data and Safety Monitoring Committee: Lawrence M. Friedman, MD (chair); Susan B. Bressler, MD; David L. DeMets, PhD; Martin Friedlander, MD, PhD; Mark W. Johnson, MD; Anne Lindblad, PhD; Douglas W. Losordo, MD, FACC; Franklin G. Miller, PhD.

Credit Roster for IVAN

Site	Investigators	Research team
Aintree University Hospitals:	Mr Ahmed Kamal Thomas Papathomas Ahmed Khalil	Pauline Guinness Richard Hancock Maria Dangler-Harles Jane Blocksage Samantha Lorenson
Aston University Birmingham¹, Birmingham Optegra Eye Hospital²:	Mr J.M.Gibson ¹ Katie Pedwell ¹ Jane Pitt ²	Ajith Kumar S. Al-Husainy S.Sreekantam M.Hanratty Tara Clark
Queen's University Belfast³, Belfast Health and Social Care Trust⁴²:	Prof Usha Chakravarthy ³ Dr Lisa Kelly ⁴ Dr Karen Gilvray ⁴	Ms Pamela Jamison Mrs Georgina Sterret Mr Vittorio Silvestri

Dr Deirdre Burns
Ms Rebecca Denham
Mrs Joanne Grattan
Mrs Teresa Rice
Mrs Lenore Ponisi

Aston University Birmingham⁵, Birmingham & Midland Eye Centre⁶:

Mr J.M.Gibson⁵
Katherine Brown⁶
Bethan Swain⁶

A.Kumar
G.Bliss
P.Cikatricis
K.Damer

Royal Blackburn Hospital:

Mrs Salwa Abugreen
Mohamed Alarbie
Debra Myerscough

H Patel
N Nixon
M Anderson
T Thompson
P Richardson

Bradford Teaching Hospitals:

Mr Faruque Ghanchi
Mrs Helen Devonport
Miss Nicci Atkinson

Julie Dixon
Tony Dook
Cara Phillips
Tomas Cudrnak
Charlotte Hazel
Mary Elliott

Sussex Eye Hospital:

Mr Anthony Casswell
Dr Gek Ong
Mr Edward Hughes

Mrs Susan Bennett
Mr Nick White
Mrs Catriona Gardiner
Mr Stephen Turner
Mrs Tenesa Sargent

Bristol Eye Hospital:

Miss Claire Bailey

Cambridge University Hospitals NHS Foundation Trust:

Mr Douglas Newman
Mr Kevin McNally

Haris Papanikolaou
Dawn Russell-Hermanns
Katherine Martin
Jo Fielden

Frimley Park Hospital NHS Foundation Trust:

Mrs Geeta Menon
Mrs Manju Chandran
Mr Gulrez Ansari

Mrs Bhavani Mathapati
Mr Nitin Jain
Mrs Lorraine North
Mrs Jincy Jose
Nadeem Rob

The Queen Elizabeth Hospital, King's Lynn NHS Foundation Trust:

Mr R J Pushapanathan
Mr I Ali

Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool⁷ and St. Paul's Eye Unit, Royal Liverpool University Hospitals NHS Trust⁸:

Prof Simon P Harding⁷
Sandra Taylor⁸
Valerie Tompkin⁸

Karen Hawkins
Jerry Sharp
Stephen Pearson

Martin Hodgson
William Hooley
Gillian Lewis

Maidstone Hospital:

Mr Frank Ahfat
Mr. Luke Membrey

Mrs. Margaret Gurney
Mr. Clive Wood
Dr. Shabeeba Hannan
Mr. Syed Idris Haider
Mr. Paul Adley

Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre & School of Biomedicine, University of Manchester:

Mr Paul N. Bishop

Ekaterina Varimezova-Georgieva

Tariq M Aslam

Newcastle upon Tyne Hospital Foundation Trust:

Mr S James Talks
Rajeev Kak

Alan Branon
Kapka Nenova
Kevin Gales

Nottingham University Hospitals Trust:

Mr Alexander Foss

Karen Armstrong-Owen

Oxford Eye Hospital, Oxford University Hospitals:

Miss Susan Downes
Miss Shahnaz Izadi
Mr Robert Purbrick

Mrs Alexina Fantato
Mrs Ivy Samuel
Miss Vicky Hart
Mrs Anna Rudenko
Mr Lewis Smith
Mr Charles Cottrill
Miss Paula Hedges

Sheffield Teaching Hospitals NHS Foundation Trust⁹, South Warwickshire NHS Foundation Trust¹⁰:

Mr Christopher Brand⁹
Dr Hibba Abdulkarim⁹
Mrs Uma Thakur¹⁰

Mrs Helen Pokora
Mr Andy Jubb
Mrs Katy Kelly
Mr Fahd Quhill
Mrs Mary Freeman

Southend Hospital:

Mr Niral Karia
Mr A Krishnan

Ms Maria Shipman
Mr John Williams
Mr Chris Johnson

Faculty of Medicine, University of Southampton¹¹, Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust¹², Southampton Eye Unit, University Hospital Southampton NHS Foundation Trust¹³:

Prof Andrew John Lotery¹¹
Marie Anne Nelson¹²
Suresh Thulasidharan¹³

Claire O'Brien
Kevin Oxlade
Caitrin Watkins
Maria Gemenetzi
Gabiella De Salvo

Sunderland Eye infirmary, Sunderland, Institute of Genetic Medicine, Newcastle University¹⁴, Sunderland Eye infirmary, Sunderland¹⁵:

Mr David Steel¹⁴

Steve Dodds

Eoghan Millar¹⁴
Vinna Manjunath¹⁵

Shelagh Thomson
Martyn Hallowell
Hugh Harris
Paula Foley

Torbay Hospital:

Mr Mick Cole
Yinka Osoba
Sanjay Dhir

Annette Field
Sharon Criddle
Karin Tilley
Eddy Doyle
Debbie Knowles

Royal Wolverhampton Hospitals NHS Trust:

Mr Yit C Yang
Nirodhini Narendran
Swathi Paneerselvam

Jas Purewal
Mary Stott
Bhagal Bhogal
Sharon Hughes
Gurminder Sahota
Jenny Nosek

Credit Roster for LUCAS

Karina Berg MD, Department of Ophthalmology, Oslo University Hospital, Oslo, Norway

Ragnheiður Bragadóttir MD PhD, Department of Ophthalmology, Oslo University Hospital, Oslo, Norway

Terje R. Pedersen MD PhD, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway

Leiv Sandvik PhD, Department of Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway

Emina Hadzalic MD, Department of Ophthalmology, Betanien Hospital, Skien, Norway

Inger Gjertsen MD, Department of Ophthalmology, Vestre Viken Hospital Trust, Drammen, Norway

Vegard Forsaa MD, Department of Ophthalmology, Stavanger University Hospital, Stavanger, Norway

Lars Haakon Berger MD, Department of Ophthalmology, Østfold Hospital, Moss, Norway

Bettina Kinge MD PhD, The Retina Clinic, Aleris, Oslo, Norway

Hans Henschien MD, Department of Ophthalmology, Vestfold Hospital, Tønsberg, Norway

Kristian Fossen MD, Department of Ophthalmology, University hospital of Northern Norway, Tromsø, Norway

Slavica Markovic MD, Department of Ophthalmology, Innlandet Hospital, Elverum, Norway